scholarly journals Metastatic Prostate Adenocarcinoma: A Rare Presentation

Cureus ◽  
2022 ◽  
Author(s):  
Pierre Rodriguez ◽  
Katayoun Khoshbin ◽  
Jay Vakil ◽  
Vaishali Deenadayalan ◽  
Ekrem Turk
2005 ◽  
Vol 32 (3) ◽  
pp. 315-318 ◽  
Author(s):  
Neville P. Shine ◽  
Peter O'Sullivan

2016 ◽  
Vol 49 (6) ◽  
pp. 242-244
Author(s):  
Che-Yuan Kuo ◽  
Shian-Shiang Wang ◽  
Chen-Hui Lee ◽  
Yen-Chuan Ou

2014 ◽  
Vol 14 (4) ◽  
pp. 271 ◽  
Author(s):  
Aye Min Soe ◽  
Sonal Bordia ◽  
Philip Q Xiao ◽  
Hernan Lopez-Morra ◽  
Juan Tejada ◽  
...  

2014 ◽  
Vol 75 (01) ◽  
pp. e81-e83 ◽  
Author(s):  
Richard Prayson ◽  
Robert Weil ◽  
Gazanfar Rahmathulla

Author(s):  
VenkataS Prathi ◽  
RakeshK Manne ◽  
Kannan Natarajan ◽  
Beeraka Swapna

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Samer Altawil ◽  
Z Ibrahim ◽  
N Sani ◽  
P Aung ◽  
S Bhatti ◽  
...  

2015 ◽  
Vol 8 (3) ◽  
pp. 526-529 ◽  
Author(s):  
Hiren Mandaliya ◽  
Joshua Sung ◽  
Joanna Hill ◽  
Ramin Samali ◽  
Mathew George

Prostate cancer is the second most common cancer in men. Diagnosis of early disease is based on prostate biopsy which is carried out because of symptoms of prostatism or asymptomatic rise in PSA. On the other side, advanced disease can locally invade and metastasise to lymph nodes, bones, lungs, etc. Initial presentation of prostate cancer in form of brain metastasis is extremely seldom. Similarly, prostate cancer, which metastasised to the breast, is very rare too. Here, we discuss two unique cases of prostate cancer, one of them had an initial presentation of brain metastasis from prostate adenocarcinoma and the other case had an established diagnosis of prostate cancer metastasised to the breast. In theory, cancer can cause metastatic spread to any part of the body; however diversity into such presentation or progression from prostate cancer has not been frequently noticed.


Author(s):  
A. Hakam ◽  
J.T. Gau ◽  
M.L. Grove ◽  
B.A. Evans ◽  
M. Shuman ◽  
...  

Prostate adenocarcinoma is the most common malignant tumor of men in the United States and is the third leading cause of death in men. Despite attempts at early detection, there will be 244,000 new cases and 44,000 deaths from the disease in the United States in 1995. Therapeutic progress against this disease is hindered by an incomplete understanding of prostate epithelial cell biology, the availability of human tissues for in vitro experimentation, slow dissemination of information between prostate cancer research teams and the increasing pressure to “ stretch” research dollars at the same time staff reductions are occurring.To meet these challenges, we have used the correlative microscopy (CM) and client/server (C/S) computing to increase productivity while decreasing costs. Critical elements of our program are as follows:1) Establishing the Western Pennsylvania Genitourinary (GU) Tissue Bank which includes >100 prostates from patients with prostate adenocarcinoma as well as >20 normal prostates from transplant organ donors.


Sign in / Sign up

Export Citation Format

Share Document